Aligos therapeutics to present data from chronic hepatitis b and hepatocellular carcinoma programs at the european association for the study of the liver (easl) congress 2023

South san francisco, calif., april 11, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the european association for the study of the liver (easl) congress 2023, taking place in vienna, austria, june 21 – 24, 2023. the presentations will be available on the scientific presentations and conferences page on aligos' corporate website following the meeting.
ALGS Ratings Summary
ALGS Quant Ranking